• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于动态复发风险变化为局部晚期食管鳞状细胞癌患者构建个体化随访策略。

Constructing individualized follow-up strategies for locally advanced esophageal squamous cell carcinoma patients based on dynamic recurrence risk changes.

作者信息

Cai Yibin, Ding Jianming, Cai XiaoJun, Su Weikun, Weng Guibin, Zheng Xinlong, Chen Shijie, Chen Lin, Lin YiJin, Yao Qiwei, Yang Chunkang

机构信息

Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.

Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.

出版信息

Sci Rep. 2025 Jan 2;15(1):175. doi: 10.1038/s41598-024-84099-4.

DOI:10.1038/s41598-024-84099-4
PMID:39747490
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11695730/
Abstract

The aim of this study was to explore the high-risk factors for recurrence in patients with locally advanced esophageal squamous cell carcinoma (ESCC) undergoing definitive chemoradiotherapy or radiotherapy (dCRT or dRT). Conditional survival (CS) was used to evaluate the dynamic survival and recurrence risk of patients after treatment, and individualized monitoring strategies were developed for patients. Logistic regression analysis was performed to determine independent recurrence risk factors. Calibration curves and receiver operating characteristic (ROC) curve were used to evaluate nomogram models. Kaplan-Meier curves were used to compare survival rates in different groups and to calculate CS rate. A total of 677 patients were included. Multivariate logistic analyses demonstrated that chemotherapy cycles, tumor length, body mass index (BMI), platelet-lymphocyte ratio (PLR), and lymphocyte-monocyte ratio (LMR) were independent recurrence risk factors (p < 0.05). Subsequently, we constructed nomogram models to predict recurrence and risk stratification. Kaplan-Meier curves showed that conditional locoregional recurrence-free survival and distant metastasis-free survival of patients in different risk groups and clinical stages progressively increased with survival time, whereas local recurrence and distant metastasis annual recurrence rates decreased yearly with increasing survival time. Finally, we developed an individualized follow-up strategy based on CS at different frequencies. Individualized follow-up strategies developed on the basis of CS can better monitor the changes in patients' conditions and contribute to timely salvage treatment and rational allocation of healthcare resources.

摘要

本研究旨在探讨接受根治性放化疗或放疗(dCRT或dRT)的局部晚期食管鳞状细胞癌(ESCC)患者复发的高危因素。采用条件生存(CS)来评估患者治疗后的动态生存和复发风险,并为患者制定个体化监测策略。进行逻辑回归分析以确定独立的复发风险因素。使用校准曲线和受试者工作特征(ROC)曲线来评估列线图模型。采用Kaplan-Meier曲线比较不同组的生存率并计算CS率。共纳入677例患者。多因素逻辑分析表明,化疗周期、肿瘤长度、体重指数(BMI)、血小板淋巴细胞比值(PLR)和淋巴细胞单核细胞比值(LMR)是独立的复发风险因素(p < 0.05)。随后,我们构建了列线图模型以预测复发和风险分层。Kaplan-Meier曲线显示,不同风险组和临床分期患者的条件性局部区域无复发生存率和远处转移无复发生存率随生存时间逐渐增加,而局部复发和远处转移的年复发率随生存时间增加逐年下降。最后,我们根据不同频率的CS制定了个体化随访策略。基于CS制定的个体化随访策略能够更好地监测患者病情变化,有助于及时进行挽救治疗和合理分配医疗资源。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c9/11695730/c8facc80c958/41598_2024_84099_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c9/11695730/7d3b3c658416/41598_2024_84099_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c9/11695730/95e6e52aec4d/41598_2024_84099_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c9/11695730/dfa899cc6cac/41598_2024_84099_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c9/11695730/a225fcdfbf6a/41598_2024_84099_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c9/11695730/d8a12a92ea9d/41598_2024_84099_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c9/11695730/c8facc80c958/41598_2024_84099_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c9/11695730/7d3b3c658416/41598_2024_84099_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c9/11695730/95e6e52aec4d/41598_2024_84099_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c9/11695730/dfa899cc6cac/41598_2024_84099_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c9/11695730/a225fcdfbf6a/41598_2024_84099_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c9/11695730/d8a12a92ea9d/41598_2024_84099_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c9/11695730/c8facc80c958/41598_2024_84099_Fig6_HTML.jpg

相似文献

1
Constructing individualized follow-up strategies for locally advanced esophageal squamous cell carcinoma patients based on dynamic recurrence risk changes.基于动态复发风险变化为局部晚期食管鳞状细胞癌患者构建个体化随访策略。
Sci Rep. 2025 Jan 2;15(1):175. doi: 10.1038/s41598-024-84099-4.
2
Survival risk stratification based on prognosis nomogram to identify patients with esophageal squamous cell carcinoma who may benefit from postoperative adjuvant therapy.基于预后列线图的生存风险分层,以确定可能从术后辅助治疗中获益的食管鳞癌患者。
BMC Cancer. 2024 Oct 29;24(1):1330. doi: 10.1186/s12885-024-13085-w.
3
Developing Individualized Follow-Up Strategies Based on High-Risk Recurrence Factors and Dynamic Risk Assessment for Locally Advanced Rectal Cancer.基于高危复发因素和动态风险评估制定局部进展期直肠癌个体化随访策略。
Cancer Med. 2024 Oct;13(20):e70323. doi: 10.1002/cam4.70323.
4
Radiotherapy and chemoradiotherapy for postoperative recurrence in patients with esophageal squamous cell carcinoma.术后复发食管癌患者的放化疗。
Cancer Med. 2024 Aug;13(16):e70108. doi: 10.1002/cam4.70108.
5
Prognostic value of pre-therapeutic nutritional risk factors in elderly patients with locally advanced esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or radiotherapy.老年局部晚期食管鳞癌患者接受根治性放化疗或单纯放疗的术前营养风险因素的预后价值。
BMC Cancer. 2023 Jun 28;23(1):597. doi: 10.1186/s12885-023-11044-5.
6
Influence of radiation dose and predicted tumor invasion depth on local recurrence after definitive chemoradiotherapy for stage 0-I esophageal squamous cell carcinoma: a propensity score-weighted, retrospective, observational study.根治性放化疗后 0 期-I 期食管鳞癌局部复发的影响因素:倾向评分加权、回顾性、观察性研究。
BMC Cancer. 2022 Mar 21;22(1):301. doi: 10.1186/s12885-022-09418-2.
7
Long-term outcomes of patients with recurrent squamous cell carcinoma of the esophagus undergoing salvage endoscopic resection after definitive chemoradiotherapy.根治性放化疗后复发的食管鳞癌患者行挽救性内镜切除的长期结果。
Surg Endosc. 2021 Apr;35(4):1766-1776. doi: 10.1007/s00464-020-07571-y. Epub 2020 Apr 30.
8
Pretreatment clinical stage predicts locoregional recurrence in patients with esophageal cancer who achieved a complete clinical response to chemoradiotherapy.治疗前临床分期可预测接受放化疗后获得完全临床缓解的食管癌患者的局部区域复发。
J Thorac Cardiovasc Surg. 2018 May;155(5):2233-2242.e2. doi: 10.1016/j.jtcvs.2017.12.082. Epub 2017 Dec 26.
9
Development of a prognostic nomogram and risk stratification system for elderly patients with esophageal squamous cell carcinoma undergoing definitive radiotherapy: a multicenter retrospective analysis (3JECROG R-03 A).老年食管鳞状细胞癌患者根治性放疗预后列线图及风险分层系统的建立:一项多中心回顾性分析(3JECROG R - 03 A)
BMC Cancer. 2025 Jan 8;25(1):40. doi: 10.1186/s12885-024-13414-z.
10
A CT-based subregional radiomics nomogram for predicting local recurrence-free survival in esophageal squamous cell cancer patients treated by definitive chemoradiotherapy: a multicenter study.基于CT的亚区域影像组学列线图预测接受根治性放化疗的食管鳞状细胞癌患者的无局部复发生存率:一项多中心研究
J Transl Med. 2024 Dec 5;22(1):1108. doi: 10.1186/s12967-024-05897-y.

本文引用的文献

1
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.《食管癌和食管胃交界癌,第2版,2023年,美国国立综合癌症网络肿瘤学临床实践指南》
J Natl Compr Canc Netw. 2023 Apr;21(4):393-422. doi: 10.6004/jnccn.2023.0019.
2
Esophageal cancer in China: Practice and research in the new era.中国食管癌:新时代的实践与研究。
Int J Cancer. 2023 May 1;152(9):1741-1751. doi: 10.1002/ijc.34301. Epub 2022 Oct 5.
3
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
食管癌:ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2022 Oct;33(10):992-1004. doi: 10.1016/j.annonc.2022.07.003. Epub 2022 Jul 29.
4
Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Factors and Reference Markers of Treatment Options for Locally Advanced Squamous Cell Carcinoma Located in the Middle and Upper Esophagus.治疗前中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值作为中上段食管局部晚期鳞状细胞癌的预后因素及治疗方案参考指标
Cancer Manag Res. 2021 Feb 5;13:1075-1085. doi: 10.2147/CMAR.S294344. eCollection 2021.
5
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
6
Prognostic value of tumor length and diameter for esophageal squamous cell cancer patients treated with definitive (chemo)radiotherapy: Potential indicators for nonsurgical T staging.根治性放化疗治疗食管鳞癌患者的肿瘤长度和直径的预后价值:非手术 T 分期的潜在指标。
Cancer Med. 2019 Oct;8(14):6326-6334. doi: 10.1002/cam4.2532. Epub 2019 Sep 4.
7
Summarizing and communicating on survival data according to the audience: a tutorial on different measures illustrated with population-based cancer registry data.根据受众总结和交流生存数据:以基于人群的癌症登记数据为例介绍不同测量方法的教程。
Clin Epidemiol. 2019 Jan 3;11:53-65. doi: 10.2147/CLEP.S173523. eCollection 2019.
8
Role of platelets and platelet receptors in cancer metastasis.血小板和血小板受体在癌症转移中的作用。
J Hematol Oncol. 2018 Oct 11;11(1):125. doi: 10.1186/s13045-018-0669-2.
9
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
10
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2.日本食管癌学会编辑的《2017年食管癌诊疗指南》:第2部分
Esophagus. 2019 Jan;16(1):25-43. doi: 10.1007/s10388-018-0642-8. Epub 2018 Aug 31.